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Reversal of somatostatin inhibition of AVP-induced cAMP by
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Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis
toxin. The effect of somatostatin on the stimulation of adenosine-3',
5'-cyclic monophosphate (cAMP) production by arginine vasopressin(AVP) was examined in rat renal papillary collecting tubule cells in
culture. The presence of phosphodiesterase inhibitor 3-isobutyl-1-me-
thylxanthine AVP at a concentration of 1 x 10—10 M or higher
significantly increased cellular cAMP levels in a dose-dependent man-
ner. The stimulation by AVP of cellular cAMP production was signifi-
cantly attenuated by I x 106 at somatostatin (1 X l0 M AVP, 477.5
23.0 vs. 292.4 28.5 fmol/pg protein per 10 mm, P <0.01). When the
cells were pretreated with pertussis toxin, pertussis toxin completely
abolished the inhibitory effect of somatostatin on cellular cAMP pro-
duction in response to AVP. Such an effect was obtained with a
concentration of 0.1 ng/ml or higher of pertussis toxin and an incubation
time of longer than an hour. The exposure of cells to 100 ng/ml pertussis
toxin for two hours recovered the cellular cAMP response to I x lO
M AVP in the presence of 1 x 10—6 M somatostatin, the value of which
527.1 32.6 fmolILg protein per 10 minutes, was a comparable level to
that in response to only 1 >< iO M AVP. Also, somatostatin inhibited
the cellular cAMP response to glucagon and cholera toxin, but did not
inhibit basal and forskolin-stimulated cAMP levels. Pertussis toxin
treatment of cells completely abolished these inhibitory effects of
somatostatin. Since it is known that pertussis toxin ADP-ribosylates a
41,000 dalton subunit of guanine nucleotide binding protein (Ni), the
present results therefore indicate that the inhibition by somatostatin of
AVP-induced cellular cAMP production is mediated via Ni to properly
couple inhibitory receptors to adenylate cyclase.
The hypothalamic peptide somatostatin has been demon-
strated to exist in a variety of tissues [1] and to inhibit the
secretion and action of a variety of hormones and neurotrans-
mitters [2—7]. In kidney, somatostatin-like immunoreactivity is
localized in the glomerulus of rat [8] and in the distal and
collecting tubules of toad [9]. Somatostatin has been shown to
inhibit the antidiuretic effect of arginine vasopressin (AVP) in
the in vivo and in situ systems; somatostatin inhibits AVP-
induced antidiuresis in dog and rat [10, 11], and AVP-induced
cellular adenosine-3', 5 '-cyclic monophosphate (cAMP) pro-
duction in the isolated, rat renal medullary, thick ascending
limb of Henle's loop and cortical and medullary collecting
tubules [12]. The mechanisms by which somatostatin elicits
such inhibitory effects are still poorly understood.
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Recent studies in GH3 or GH4C1 clonal, rat pituitary cell
strain suggested that the inhibitory effect of somatostatin on
vasoactive intestinal polypeptide (VIP)-induced prolactin re-
lease is mediated by changes in cAMP levels [13, 14]. This
interaction was further evaluated by the use of pertussis toxin,
a protein produced by Bordetella pertussis [15], which ADP-
ribosylates a 41,000 dalton subunit of inhibitory guanine nude-
otide binding protein (Ni) [16]. In clonal rat pituitary cells the
action of somatostatin requires a functional Ni [13, 14]. Similar
results were also obtained in several types of endocrine cells,
including pancreatic beta cells [15], pituitary somatotrophs [17],
and AtT-20/D-16 pituitary tumor cells [18].
The present study was undertaken to determine whether
somatostatin inhibits cellular cAMP production in response to
AVP in rat renal papillary, collecting tubule cells in culture. We
further examined the interaction with use of pertussis toxin to
address the role of Ni in somatostatin action in renal papillary
collecting tubule.
Methods
Cell culture
The experimental procedure was similar to our previous
studies [19, 20], modified from the study of Grenier, Rollins and
Smith [21]. Briefly, male Sprague-Dawley rats weighing 150 to
175 g were used. Each rat was decapitated and the abdomen
immediately rinsed with iodine (1% in 70% ethanol). Under
sterile conditions the abdominal wall was cut, and both kidneys
were removed and placed in 20 ml sterile Krebs-Ringer buffered
saline (128 m NaCl, 5mM KCI, 1.2 mr'i MgSO4, 0.8mM CaCl2,
10 m sodium acetate, 10 m glucose, 10 mr'i Tris, and 2 mM
NaH2PO4, pH 7.4). Six kidneys from three rats were grouped
together and two or three groups were prepared at each time.
Renal papillary tissues were dissected out and minced with 1 ml
collagenase (1 mg/ml; type II, Cooper Biochemical Inc., Free-
hold, New Jersey, USA) using a sharp blade. The minced renal
papillary tissues were transferred into culture tubes (Corning
15-ml culture tubes, Corning, Midfield, Massachusetts, USA)
containing 3 ml collagenase (1 mg/mI) and kept at 37°C in a
humidified incubator for an hour and half. During this incuba-
tion period the tubes were gently shaken every 30 minutes to
resuspend the precipitated tissues. Distilled water (3 ml) was
added to the tubes to produce a hypotonic disruption of the red
blood cells. The suspension was then drawn up and down by a
pipette to break any tissue clump before the tubes were
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centrifuged at 500 x g for four minutes at room temperature and
the supernatants removed by aspiration. The pellets were
resuspended in 10 ml of 10% bovine serum albumin (Sigma, St.
Louis, Missouri, USA), dissolved in Krebs-Ringer buffered
saline, and centrifuged again as described above. After aspiration
of the supernatants the pellets were resuspended in Dulbecco's
modified Eagle's Minimal Essential Medium (DMEM; Flow
Laboratories, McLean, Virginia, USA) supplemented with 10%
bovine fetal serum, 100 U/ml penicillin, 100 p.g/ml streptomycin,
and 2.5 tg/ml fungizone, with an osmolality of 600 mOsm/kg
H20. The hypertonic DMEM was prepared by adding NaCI and
urea in a molar ratio of 1:2 to the standard DMEM (300
mOsm/kg H20) [20, 221. The dispersed cells and tubules were
harvested into a total of 72 or 108 wells of 24-well tissue culture
clusters (Costar, Cambridge, Massachusetts, USA) with 1 ml
DMEM containing 10% bovine fetal serum, penicillin, strepto-
mycin and fungizone, and kept in a humidified incubator under
95% air and 5% CO2. On the second day of culture the medium
was changed to 1 ml 99% DMEM containing 1% bovine fetal
serum, 5 g/ml insulin (Sigma), 5 gIml transferrin (Sigma), 5 x
10-8 M hydrocortisone (Calbiochem-Boehringer, La Jolla, Cal-
ifornia, USA), 5 x 10-8 M triiodothyronine (Sigma), 100 U/mI
penicillin, 100 pg/ml streptomycin, and 2.5 pg/ml fungizone,
which had an osmolality of 600 mOsm/kg H20 and was prepared
as described earlier. This hormone supplemented medium was
modified from Taub and associates [23]. When grown to sub-
confluency on day 5 and examined by light microscopy, the
cultured cells were homogenously polygonal, similar to the
study by Grenier, Rollins and Smith [211.
Effect of somatostatin on cellular cAMP production
On the fifth day of culture the cells were rinsed twice with 1
ml of Krebs-Ringer buffered saline (600 mOsm/kg H2O) and
then incubated with 1 ml of the effector for 10 minutes at 37°C
in a humidified incubator. The effectors included AVP (grade
VI, Sigma), glucagon (Peptides Institute, Osaka, Japan), cholera
toxin (List Biol. Lab., Campbell, California, USA), forskolin
(Nippon Kayaku Pharmaceutical Co., Tokyo, Japan) or soma-
tostatin (Peptides Institute), together with 5 X l0— M 3-
isobutyl-l-methylxanthine (Nakarai Biochem. Co., Tokyo, Ja-
pan) which inhibits the phosphodiesterase activity. Forskolin
was dissolved in ethanol and 3-isobutyl-l-methylxanthine was
dissolved in 50 mi NaOH; both were diluted with Krebs-
Ringer buffered saline (600 mOsm/kg H2O). Other substances
were directly dissolved in the hypertonic Krebs-Ringer buffered
saline. Control experiments were performed in the same man-
ner with the vehicles. After the incubation period the AVP,
glucagon, cholera toxin and/or somatostatin solutions were
removed by aspiration. The cells were immediately immersed in
0.2 ml of 0.1 N HC1 to stop the reaction. They were then
collected into glass tubes (6 x 50 mm) with a rubber policeman.
The cells were boiled for three minutes. After centrifuging the
tubes at 2,500 x g for 15 minutes at room temperature the
supernatants were carefully decanted and 0.05 ml of 50 msi
sodium acetate was added. The supernatants were kept at
—20°C until the time of assay for cAMP, cAMP was assayed by
radioimmunoassay, using cAMP kits obtained from Yamasa
Inc. (Choshi, Japan) [24]. Also, in a part of experiments
extracellular cAMP concentrations were measured. The pellets
were dissolved in 0.2 ml of 1% sodium dodecylsulphate and
kept at 4°C until the time of assay for protein. Protein was
measured by the method of Lowry et al [251.
Effect of pertussis toxin on cellular cAMP production
On the fifth day of culture the cells were rinsed twice with I
ml Krebs-Ringer buffered saline (600 mOsm/kg H2O) and pre-
incubated with pertussis toxin for an indicated time at 37°C in a
humidified incubator. Pertussis toxin was purified from a cul-
ture medium of Bordetella pertussis (Tohama strain, phase I)
and stored in 0.05 M Tris-HCI buffer (pH 8.0) containing 1 M
NaCI and 50% (wt/vol) glycerin at —20°C [26], which was
dissolved in the hypertonic Krebs-Ringer buffered saline. If the
preincubation time was more than three hours, the preincuba-
tion of cells with pertussis toxin was carried out with the
hypertonic, hormone-supplemented DMEM. Treatment with
pertussis toxin did not affect the viability of the cultured cells,
as trypan blue stained less than 1% of the cells, The cells were
rinsed and then incubated for 10 minutes at 37°C in a humidified
incubator, with 1 ml the effectors described earlier together
with pertussis toxin and 5 x l0 M 3-isobutyl-l-methylxan-
thine. Control experiments were performed in the same manner
with the vehicle in the presence or absence of pertussis toxin.
After the incubation period the effector solutions were aspirated
off and the cells were immediately immersed with 0.2 ml of 0.1
N HCI to stop the reaction. The residual experimental proce-
dure was similar to that described above, and cellular cAMP
and protein were measured.
Statistics
All values of cellular cAMP concentrations were compared
by an analysis of variance and unpaired Student's t-test as
necessary. A P value less than 0.05 was considered significant.
Results
Figure 1 shows the effect of pertussis toxin on the inhibition
by somatostatin of AVP-induced cellular cAMP production (A)
and medium cAMP concentrations (B). A submaximal stimu-
lated concentration of 1 X iO M AVP significantly increased
the cellular cAMP level to 594.7 45.8 fmol/.tg protein per 10
minutes. However, response of cellular cAMP production to I
X i0 M AVP was significantly reduced by the presence of 1 x
10—6 M somatostatin (P < 0.01). In the present study, after the
cells were preincubated with varying concentrations of pertus-
sis toxin for two hours, the cells were exposed to a mixture of
I x l0 M AVP and I x 10_6 M somatostatin for additional 10
minutes. When the concentration of pertussis toxin was more
than 0.1 ng/ml, it significantly blocked the inhibitory effect of
somatostatin on cellular cAMP production. In contrast, pertus-
sis toxin did not affect the cellular cAMP levels in the cells
incubated with 1 x l0_6 M somatostatin. Quite similar changes
in medium cAMP concentrations were obtained (Fig. lB).
Time course of the effect of pertussis toxin on somatostatin
inhibition of cellular cAMP levels in response to 1 X l0 M
AVP in rat renal papillary collecting tubule cells in culture is
depicted in Figure 2. AVP-stimulated cellular cAMP level was
significantly lowered by the presence of 1 X lO_6 M somato-
statin, as compared to its absence (987.9 39.7 vs. 750.6 46.5
fmoUpg protein per 10 mm, P < 0.01). Pretreatment of cells
with 100 ng/ml pertussis toxin for more than an hour abolished
the inhibitory effect of somatostatin and recovered the response
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Fig. 1. Reversal by pertussis toxin of somatostatin inhibition of cellu-
lar cAMP production (A) and medium cAMP concentration (B) in
response to AVP in renal papillary collecting tubule cells in culture.
Symbols are: (U) basal cAMP level; (D) cAMP level in response to 1 x
10 M AVP; (•) basal cAMP levels in pertussis toxin-treated cells
exposed to I x 10 M somatostatin; and (0) cAMP levels in response
to a mixture of 1 X 10 M AVP and 1 >< 10-6 M somatostatin in
pertussis toxin-treated cells; (*) and (**) mean P <0.05 and P < 0.01
vs. the level stimulated by a mixture of 1 x IO M AVP and 1 x 10—6
M somatostatin in the absence of pertussis toxin, respectively. Values
are the means SEM, N = 6.
Time, hours
Fig. 2. Time course of the effect of pertussis toxin on somatostatin
inhibition of cellular cAMP production in response to I x 10 MA VP.
Symbols are (•) basal cAMP level; (EJ) cAMP level in response to 1 x
iO M AVP; (•)basal cAMP levels in 100 ng/ml pertussis toxin-treated
cells exposed to I x 10—6 M somatostatin; and (0) cAMP levels in
response to a mixture of 1 x iO M AVP and 1 x 106 M somatostatin
in 100 ng/ml pertussis toxin-treated cells; (*) and (**) mean P < 0.05 and
P < 0.01 vs. the level stimulated by a mixture of I X l0— M AVP and
1 x 10—6 M somatostatin in the absence of pertussis toxin, respectively.
Values are the means SEM, N = 6.
Table 1. Effect of pertussis toxin on cellular cAMP production in
response to AVP in rat renal papillary, collecting tubule cells
Pertussis
No pertussis
toxin
Toxins
100 ng/ml P value
Vehicle 259.6 20.5 308.7 14.2 NS
1 x l0 M AVP 557.9 42.5 670.5 53,8 NS
1 x iO M AVP 633.4 37.8 708.2 46.3 NS
nglml pertussis toxin for two hours completely blocked the
inhibition by 1 x 10-6 M somatostatin of cellular cAMP levels in
response to AVP. Also, the pertussis toxin treatment tended to
augment the cellular cAMP production in response to AVP in
the cells simultaneously exposed to somatostatin with the
concentration less than I x 10-6 NI.
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a The cells were exposed to 100 ng/ml pertussis toxin for two hours
before the start of experiments. Values are the means SEM, N = 6.
of cellular cAMP production to 1 x i0 M AVP. Preincubation
time of two hours with pertussis toxin was thus used in most of
the present studies. Basal cellular cAMP levels were not altered
by 1 x 10-6 M somatostatin in the cells with or without the
pertussis toxin treatment.
Table I shows the effect of pertussis toxin on AVP-induced
cellular cAMP production in the cultured cells. The treatment
of cells with 100 nglml pertussis toxin for two hours had a
tendency to augment the cAMP production in response to 1 X
io" and 1 X iO M AVP, but it was nOt statistically significant.
Figure 3 shows the inhibitory effect of somatostatin on
cellular cAMP production in response to AVP. The study was
carried out with varying concentrations of somatostatin ranging
from 1 x 10b0 to 1 x 10_6 M. Only the 1 x 10-6 M concentra-
tion significantly inhibited cellular cAMP level induced by 1 x
10 NI AVP (P < 0.05). The pretreatment of cells with 100
Reversal by pertussis toxin of somatostatin inhibition of
cellular cAMP production in response to AVP in rat rtnal
papillary, collecting tubule cells in culture is depicted in Figure
4. AVP caused an increase in cellular cAMP levels in a
dose-dependent manner. When the cells were incubated with a
mixture of 1 x 10—6 M somatostatin and AVP cellular cAMP
levels were significantly less than those stimulated by only
AVP. The inhibitory effect of somatostatin was abolished by the
pretreatment with pertussis toxin. On the other hand, somato-
statin had no effect on cellular cAMP response to forskolin (Fig.
5). Forskolin produced a dose-depender't increase in cellular
cAMP levels, which remained unchanged in the presence of 1 x
10_6 M somatostatin. Also, the exposure of cells to pertussis
toxin did not alter the cellular cAMP response to forskolin.
Table 2 shows the effect of somatostatin on cellular cAMP
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Fig. 3. Effect of somatostatin on cellular cAMP levels in response to
AVP in renal papillary, collecting tubule cells in culture. Symbols are:
(•) basal cAMP levels; (0) 1 x lO— at AVP-stimulated cellular cAMP
levels; and (0) cellular cAMP levels in response to I X iO M AVP in
100 ng/ml pertussis toxin-treated cells. (*) P < 0.05 vs. the level
stimulated by only 1 x l0— M AVP. Values are the means SEM, N
= 6.
AVP, Mo!
Fig. 4. Reversal by pertussis toxin of somatostatin inhibition of cellu-
lar cAMP production in response to A VP in renal papillary, collecting
tubule cells in culture. Symbols are: (•) AVP-stimulated cellular cAMP
levels; (0) cAMP levels in response to a mixture of AVP and I x 106
at somatostatin; and (0) cAMP levels in response to a mixture of AVP
and I x 10—6 M somatostatin in 100 ng/ml pertussis toxin-treated cells.
(*) and (**) mean P < 0.05 and P < 0.01 vs. the each corresponding
level stimulated by only AVP. Values are the means SEM, N = 6.
production in response to glucagon. Glucagon increased cellu-
lar cAMP levels in a dose-dependent manner. Cellular cAMP
production in response to 1 x lO at glucagon was significantly
attenuated by 1 x 10—6 M somatostatin. Exposure of cells to 100
nglml pertussis toxin for two hours reversed the inhibitory
effect of somatostatin on cellular cAMP levels in response to 1
x l0 and 1 x 10—6 M glucagon. Similar results were obtained
with cholera toxin (Table 3). Somatostatin significantly inhib-
ited cellular cAMP levels in response to 5 ng/ml and 500 ng!ml
cholera toxin, and the inhibition disappeared with the pretreat-
ment with pertussis toxin.
Discussion
The present study clearly demonstrated that somatostatin
inhibited cellular cAMP production in response to AVP in rat
renal papillary, collecting tubule cells in culture. AVP at a
concentration of 1 x l0°M or higher caused a dose-dependent
increase in cellular cAMP production, which was significantly
attenuated by the presence of 1 x 106M somatostatin. Soma-
tostatin, however, did not affect the basal level of cellular
cAMP. Similar results were obtained from other laboratories
using the in situ and in vitro systems [10—12, 27, 28]. In the
isolated rat renal, medullary thick ascending limb of Henle's
loop and cortical and medullary collecting tubules, and in pig
kidney, epithelial cell line LLC-PKIL cells, somatostatin inhib-
its AVP induced increase in adenylate cyclase activity or cAMP
production. In these studies the inhibitory effect of somato-
statin was found with a concentration of 1 x 10-6 M or higher.
This seems to be a high concentration for somatostatin to inhibit
cAMP production as compared to the endocrine cells. Further-
more, we found inhibition of cellular cAMP production by
somatostatin in response to glucagon and cholera toxin in the
cultured cells. We did not examine interactions between sodium
fluoride or 5'-guanylylimidodiphosphate and somatostatin in the
present study, since sodium fluoride and 5'-guanylylimidodi-
phosphate did not have any stimulatory effect on cellular cAMP
production in the cultured cells we have handled [20]. How-
ever, somatostatin did not affect cellular cAMP levels in re-
sponse to forskolin. Forskolin is a diterpene activator of ade-
nylate cyclase directly stimulating at the catalytic unit [29], and
cholera toxin, a protein produced by Vibrio Cholerae, directly
affects guanine nucleotide regulatory proteins (Ns), followed by
a stimulation of catalytic unit [301. In contrast, the activation of
adenylate cyclase by AVP in renal collecting tubule is initiated
by binding to the AVP receptor on the antiluminal plasma
membrane, followed by stimulation of Ns and catalytic unit
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Fig. 5. No effect of somatostatin and pertussis toxin on cellular cAMP
production in response to forskolin. Symbols are: (•) forskolin-stim-
ulated cellular cAMP levels; (0) cAMP levels in response to a mixture
of forskolin and 1 x 10—6 M somatostatin; and (0) cAMP levels in
response to a mixture of forskolin and I x 10—6 M somatostatin in 100
ng/ml pertussis toxin-treated cells. Values are the means SEM, N = 6.
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Table 2. Effect of somatostatin and pertussis toxin on cellular cAMP production in response to glucagon in rat renal papillary, collecting
tubule cells
Pertussis
Controla
Somatostati&'
lx 1tV6M
toxin
Somatostatin
Ix 106M
.
F values
avs.b avs.c bvs..c
Vehicle 178.7 11.3 214.9 33.0 238.2 22.4 NS <0.05 NS
Glucagon1 x lO M 182,7 18.0 168.3 17.2 218.5 13.9 NS NS NS
1 x io— M 325.3 37,It 278.9 11.9 322.1 31.1 NS NS NS
1 )< 1U M 403.8 29.9e 302.1 26.5 439.8 33.1e <0.05 NS <0.05
1 x 10—6 M 507.8 23.4e 435.3 23.2c 596.7 41,2e NS NS <0.01
d Tbe cells were exposed to 100 ng/ml pertussis toxin for two hours before the start of experiments.
P < 0.01 vs. the vehicle group. Values are the means 5EM, N =6.
Table 3. Effect of somatostatin and pertussis toxin on cellular cAMP production in response to cholera toxin in rat renal papillary, collecting
tubule cells
Pertussis
Controla
Somatostatinb
lx 106M
toxin
Somatostatin
lx l06M
P values
avs.b avs.c bvs.c
Vehicle 187.7 15.4 171.8 13.5 217.2 26.4 NS NS NS
Cholera toxin
5 ag/mI 254.8 26.0t 169.8 14.5 268.5 26.4 <0.05 NS <0.01
50 ng/ml 437.4 27.1 373.4 2o.8 547.1 290r NS <0.05 <0.01
500 ng/ml 452.7 24.0 309.4 27.V 444.8 l2.3 <0.01 NS <0.01
d The cells were exposed to 100 ng/ml pertussis toxin for two hours before the start of experiments.
F < 0.05 vs. the vehicle group
<0.01 vs. the vehicle group
Values are the means 5CM, N = 6.
[31]. The present finding of somatostatin inhibition of cAMP
production indicates that somatostatin may interact with the Ns
mediated stimulations. A study by Katada, Oinuma and Ui [32]
also demonstrated no inhibition by an inhibitory guanine nude-
otide binding protein (Ni) of forskolin-induced adenylate cy-
clase in rat brain. This is compatible with our results showing
Ni protein attenuated receptor Ns-stimulated, catalytic unit of
adenylate cyclase. These sites at which Ns and forskolin
interact with the catalytic unit seem likely to be different from
each other [32]. In LLC-PKIL cells somatostatin does not
interfere with [3H]-labeled AVP binding to receptors [28], and
thus the inhibitory effect of somatostatin is suggested to act at
a site distal to the AVP receptor. Glucagon has a weak effect on
outer and inner medullar collecting tubules [33]. Glucagon and
AVP effects were observed to be non-additive in the papillary
collecting tubule cells (data not shown), indicating these two
hormones stimulate a common pool of adenylate cyclase in the
structure, as suggested in cortical and medullary ascending limb
of Henle's loop [34]. It is apparent that somatostatin inhibited
the effect of glucagon, as the stimulation by glucagon of cAMP
production is also mediated through Ns. The findings that
pertussis toxin was effective in altering cAMP production in
response to glucagon and cholera toxin in the presence of
somatostatin is thus acceptable, and this interpretation is dis-
cussed below.
Pertussis toxin completely abolished the inhibitory effect of
somatostatin on cellular cAMP production in response to AVP.
Such an effect of pertussis toxin was obtained with a concen-
tration of more than 0.1 ng/ml and an incubation time of longer
than an hour. We performed the treatment of cells by pertussis
toxin (100 ng/ml) for two hours in the present study. This
maneuver was identical to our previous study [14]. A slightly
but not significantly high level of cellular cAMP in response to
AVP in the presence of somatostatin was obtained with 100
ng/ml pertussis toxin (Figs. 2 and 3). This may be influenced by
the inhibition of Ni by pertussis toxin, as the pertussis toxin
treatment mimicked the cellular level of cAMP in response to
AVP (Table 1). It is known that pertussis toxin ADP-ribosylates
a 41,000 dalton subunit (a-subunit) of guanine nucleotide regu-
latory protein (Ni) [16]. In pituitary cells the somatostatin
receptors are identified and are likely to regulate adenylate
cyclase via Ni [13, 14]. In kidney there is no report to show the
presence of somatostatin in renal tubules, but Kurokawa and
associates demonstrated the presence of immunoreactive soma-
tostatin in glomerulus, using radioimmunoassay and immuno-
cytochemistry [8]. Following pertussis toxin treatment of cells,
somatostatin-mediated inhibition of cAMP production was
blocked. This action bf pertussis toxin is thus believed to result
from the inability of ADP-iibosylated Ni to properly couple
receptors of inhibitory agonists to adenylate cyclase. Katada,
Oinuma and Ui [32] showed that Ni has a heterotrimeric
structure with 41,000 (a), 35,000 (/3), and 10,000 dalton subunits
C)'). a-Subunit (41,000 dalton) inhibited the catalytic unit of
adenylate cyclase only when the catalytic unit was activated by
Ns. ADP ribosylation of a-subunit by pertussis toxin, however,
did not affect a-subunit induced inhibition of the catalytic unit.
Ishikawa et a!: A VP somatostatin interaction and Ni 541
Thus, it is suggested that the capability of Ni (cs/3y-subunits) to
couple to receptors is selectively impaired by ADP ribosylation
of the a-subunit. The present study therefore confirms that
renal papillary collecting tubule has Ns and Ni proteins to
regulate adenylate cyclase activation, and the inhibitory effect
of somatostatin on AVP-induced cellular cAMP production is
mediated through Ni.
There are a few reports of pertussis toxin use in renal tubules.
Prostaglandin E2 antagonizes the antidiuretic effect of AVP via
an inhibition of adenylate cyclase in collecting tubules [31].
Pertussis toxin treatment diminished the inhibitory effect of
prostaglandin E2, thus indicating that antagonism of prostaglan-
din E2 to the action of AVP may be mediated by Ni in renal
tubules [35, 36]. Also, the same laboratory showed that pertus-
sis toxin prevents homologous desensitization of adenylate
cyclase induced by AVP in cultured rat renal, cortical collecting
tubule cells [37]; this was not confirmed by others [381, how-
ever. Further study is needed to explore the exact mechanism
for Ni to alter renal responses to hormones.
In summary, we have examined the role of somatostatin in
the cellular action of AVP on cAMP production in the cultured
rat renal, papillary collecting tubule cells. Somatostatin signif-
icantly attenuated cellular cAMP production in response to
AVP. Also, somatostatin inhibited cellular cAMP production in
response to glucagon and cholera toxin, but did not affect basal
and forskolin-induced cellular cAMP levels. Pertussis toxin
treatment of cells completely abolished these inhibitory effects
of somatostatin on cellular cAMP production. These results
indicate that the inhibition by somatostatin of AVP-induced
cellular cAMP production is mediated via Ni to properly couple
inhibitory receptors to adenylate cyclase.
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